Cybin (OTCMKTS:CYBN) Trading Down 5.3%

Cybin Inc. (OTCMKTS:CYBN)’s stock price was down 5.3% during mid-day trading on Thursday . The company traded as low as $0.40 and last traded at $0.41. Approximately 5,637,068 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 5,370,952 shares. The stock had previously closed at $0.43.

Cybin Price Performance

The stock’s fifty day simple moving average is $0.37 and its 200-day simple moving average is $0.43. The company has a market capitalization of $167.30 million, a P/E ratio of -1.94 and a beta of 0.38.

Cybin (OTCMKTS:CYBN) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). On average, research analysts predict that Cybin Inc. will post -0.19 earnings per share for the current year.

Institutional Investors Weigh In On Cybin

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC boosted its holdings in Cybin by 104.0% during the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after acquiring an additional 46,129 shares during the period. Royal Bank of Canada lifted its stake in shares of Cybin by 926.4% in the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock valued at $52,000 after buying an additional 98,596 shares during the period. Jane Street Group LLC lifted its stake in shares of Cybin by 370.6% in the first quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock valued at $61,000 after buying an additional 58,771 shares during the period. Belpointe Asset Management LLC lifted its stake in shares of Cybin by 21.5% in the first quarter. Belpointe Asset Management LLC now owns 313,705 shares of the company’s stock valued at $121,000 after buying an additional 55,600 shares during the period. Finally, Penserra Capital Management LLC lifted its stake in shares of Cybin by 55.8% in the first quarter. Penserra Capital Management LLC now owns 407,309 shares of the company’s stock valued at $223,000 after buying an additional 145,929 shares during the period. 2.02% of the stock is currently owned by institutional investors.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.